Floatz logo

Irinotecan

Hepatocellular Carcinoma

Icahn School of Medicine at Mount SinaiSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
65/ 100

Competitive context

262 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Theprubicin
RWTH Aachen University
Phase 4BB
Calcium folinate pentahydrate
Li Qiang
Phase 4BB
Eloxatin
Li Qiang
Phase 4BB
Ethiodized Oil
RWTH Aachen University
Phase 4BB
Inno-206
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →